PCSK9 Inhibitors Market
完整報告名稱與涵蓋範圍
PCSK9 Inhibitors Market Size, Share & Trends Analysis Report By Product Type (Repatha (Evolocumab), Praluent (Alirocumab), Bococizumab, Others), By Application (Clinical Application, Drug Development, Other), By Region, And By Segment Forecasts, 2025-2034
報告摘要
Across the 2025 to 2034 projection horizon, the worldwide PCSK9 Inhibitors Market is projected to register a CAGR of 15.0%.
The PCSK9 Inhibitors sector involves key industry insights & findings from the report:
There represents a higher demand for novel treatments that can efficiently control chronic illnesses like high cholesterol. This domain has witnessed marked transformation owing to technological breakthroughs and shifting healthcare dynamics.
Several factors contribute to this trajectory, including heightened need next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
From a regional perspective, mature markets in North America and Europe continue to hold marked shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and escalating investment in the sector.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global PCSK9 Inhibitor Market Snapshot
Chapter 4. Global PCSK9 Inhibitor Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2021-2034
4.8. Global PCSK9 Inhibitor Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2021)
4.10. Use/impact of AI on PCSK9 Inhibitor Market Industry Trends
Chapter 5. PCSK9 Inhibitor Market Segmentation 1: By Drug, Estimates & Trend Analysis
5.1. Market Share by Drug, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drug:
5.2.1. Alirocumab
5.2.2. Evolocumab
5.2.3. Inclisiran
5.2.4. Pipeline Drugs
5.2.4.1. Ebronucimab
5.2.4.2. Tafolecimab
5.2.4.3. Lerodalcibep
5.2.4.4. MK-0616
Chapter 6. PCSK9 Inhibitor Market Segmentation 2: By Modality, Estimates & Trend Analysis
6.1. Market Share by Modality, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Modality:
6.2.1. Fully-humanized Monoclonal Antibodies
6.2.2. siRNA
Chapter 7. PCSK9 Inhibitor Market Segmentation 3: By Indication, Estimates & Trend Analysis
7.1. Market Share by Indication, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
7.2.1. Primary Hyperlipidemia
7.2.2. Familial Hyper Cholesterolemia
7.2.3. Atherosclerotic Cardiovascular Disease (ASCVD)
7.2.4. Prevention of Other Cardiovascular Events
Chapter 8. PCSK9 Inhibitor Market Segmentation 4: By Sales Channel, Estimates & Trend Analysis
8.1. Market Share by Sales Channel, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Sales Channel:
8.2.1. Hospitals
8.2.2. Specialty Clinics
8.2.3. Retail Pharmacies
8.2.4. Online Pharmacies
Chapter 9. PCSK9 Inhibitor Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global PCSK9 Inhibitor Market, Regional Snapshot 2024 & 2034
9.2. North America
9.2.1. North America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2021-2034
9.2.3. North America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Modality, 2021-2034
9.2.4. North America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.2.5. North America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2021-2034
9.3. Europe
9.3.1. Europe PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.3.2. Germany
9.3.3. U.K.
9.3.4. France
9.3.5. Italy
9.3.6. Spain
9.3.7. Rest of Europe
9.3.8. Europe PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2021-2034
9.3.9. Europe PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Modality, 2021-2034
9.3.10. Europe PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.3.11. Europe PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2021-2034
9.4. Asia Pacific
9.4.1. Asia Pacific PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.4.2. India
9.4.3. China
9.4.4. Japan
9.4.5. Australia
9.4.6. South Korea
9.4.7. Hong Kong
9.4.8. Southeast Asia
9.4.9. Rest of Asia Pacific
9.4.10. Asia Pacific PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2021-2034
9.4.11. Asia Pacific PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Modality, 2021-2034
9.4.12. Asia Pacific PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.4.13. Asia Pacific PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2021-2034
9.5. Latin America
9.5.1. Latin America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.5.2. Brazil
9.5.3. Mexico
9.5.4. Rest of Latin America
9.5.5. Latin America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2021-2034
9.5.6. Latin America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Modality, 2021-2034
9.5.7. Latin America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.5.8. Latin America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2021-2034
9.6. Middle East & Africa
9.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.6.2. GCC Countries
9.6.3. Israel
9.6.4. South Africa
9.6.5. Rest of Middle East and Africa
9.6.6. Middle East & Africa PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2021-2034
9.6.7. Middle East & Africa PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Modality, 2021-2034
9.6.8. Middle East & Africa PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.6.9. Middle East & Africa PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Regeneron Pharmaceuticals, Inc. (Sanofi)
10.2.1.1. Business Overview
10.2.1.2. Key Product/Service Overview
10.2.1.3. Financial Performance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. Amgen Inc.
10.2.3. Novartis AG
10.2.4. Innovent
10.2.5. CiVi Biopharma
10.2.6. LIB Therapeutics, LLC
10.2.7. Akeso Pharmaceuticals Inc.
10.2.8. Shanghai Junshi Biosciences Co., Ltd
10.2.9. Merck & Co., Inc.
10.2.10. AstraZeneca
10.2.11. Alnylam
10.2.12. Affiris
10.2.13. BMS
10.2.14. Ionis Pharmaceuticals
10.2.15. Cyon Therapeutics
10.2.16. Daiichi Sankyo
10.2.17. Other Market Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們